Based on a world-class R&D engine, Lycera has built a robust proprietary pipeline of selective immune modulators for the treatment of autoimmune diseases.  The Company’s lead program LYC-30937-EC completed Phase 1 clinical testing in healthy volunteers in December 2015.  In August of 2016, Lycera announced the initiation of a Phase 2 randomized, placebo controlled clinical trial for LYC-30937-EC, in patients with ulcerative colitis (UC). In November of 2016, Lycera announced the start of a Phase 2 randomized, double-blind, placebo-controlled parallel group study designed to assess the efficacy and safety of LYC-30937-EC given orally once daily in subjects with moderate psoriasis.